People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | — | Biotechnology | Series D+ | $282.2M | $940.0M | 2019 |
| SutroVax, Inc. | — | Biotechnology | Series D+ | $205.9M | $4.5B | 2017 |
| Kolltan Pharmaceuticals Inc | — | Biotechnology | Series C | $137.0M | $2.5B | 2008 |
| Escient Pharmaceuticals Inc | — | Biotechnology | Series C | $108.8M | $994.9M | 2020 |
| Alios Biopharma Inc | — | Pharmaceuticals | Series C | $82.3M | $1.4B | 2008 |
| Iconic Therapeutics Inc | — | Biotechnology | Series C | $79.0M | $533.7M | 2015 |
| TRex Holdings Inc. | — | Biotechnology | Series C | $42.3M | $329.3M | 2024 |
Peter Hirth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Hirth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jack Nielsen | 2 | 13 |
| Lawrence Blatt | 2 | 3 |
| Kathleen Glaub | 2 | 3 |
| K. Peter Hirth | 2 | 2 |
| Leonid Beigelman | 2 | 2 |
| Michael Ross | 1 | 18 |
| Andrew Schwab | 1 | 16 |
| Todd Foley | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Patrick Enright | 1 | 10 |
| Joel Marcus | 1 | 9 |
| Campbell Murray | 1 | 9 |
| Jens Eckstein | 1 | 8 |
| Alexandra Cantley | 1 | 8 |
| John Donovan | 1 | 8 |
| Bruce Robertson | 1 | 7 |
| Bruce Cohen | 1 | 7 |
| Patrick J. Heron | 1 | 7 |
| William Greene | 1 | 6 |
| Peter Moldt | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.